REG - Venture Life Group - Result of AGM

Venture LifeAnnouncement

03/06/2020 10:55

RNS Number : 8231O
  
Venture Life Group PLC
  
03 June 2020
  
 

3 June 2020
Venture Life Group plc
("Venture Life" or the "Group")
Result of AGM
Venture Life Group plc (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, announces that at its closed Annual General Meeting held earlier today, that all resolutions were duly passed.
 
 
For further information, please contact:
 




Venture Life Group PLC


+44 (0) 1344 578004




Jerry Randall, Chief Executive Officer
Andrew Waters, Chief Financial Officer


 




 
Cenkos Securities plc (Nomad and Broker)


 
+44 (0) 20 7397 8900




Stephen Keys / Mark Connelly / Cameron MacRitchie (Corporate Finance)


 




Russell Kerr / Michael Johnson (Sales)


 



 
 
 



 
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, The Netherlands and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare, fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing.
 
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands, these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 
 
Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies for consumer healthcare products, primarily medical devices.
 
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
RAGUOSKRRKUNRRR